Evaluation of dosing strategy for pembrolizumab for oncology indications

BACKGROUND: Traditionally, most monoclonal antibodies (mAbs) have been dosed based on body weight because of perceived contribution of body size in pharmacokinetic variability. The same approach was used in the initial pembrolizumab studies; however, following availability of PK data, the need for w...

Descripción completa

Detalles Bibliográficos
Autores principales: Freshwater, Tomoko, Kondic, Anna, Ahamadi, Malidi, Li, Claire H., de Greef, Rik, de Alwis, Dinesh, Stone, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433037/
https://www.ncbi.nlm.nih.gov/pubmed/28515943
http://dx.doi.org/10.1186/s40425-017-0242-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433037/
https://www.ncbi.nlm.nih.gov/pubmed/28515943
http://dx.doi.org/10.1186/s40425-017-0242-5

Ejemplares similares